We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Diagnostic Technology Licensed to Bayer

By Labmedica staff writers
Posted on 13 Jul 2005
Print article
DNA diagnostic technology has been licensed to Bayer HealthCare, Diagnostics Division (Leverkusen, Germany), by DxS (Manchester, UK; www.dxsgenotyping.com) and BTG (London, UK) in order for Bayer to develop diagnostic assays, including pharmacogenetic assays.

The new technology, called Amplification Refractory Mutation System (ARMS), was developed by DXS and BTG. Bayer is interested in developing assays that will enable healthcare professionals to optimize healthcare delivery by better predicting an individual's genetic likelihood for disease onset and maximizing disease treatment success by matching a person's unique genetic make-up to the therapy. ARMS is a reliable method for the detection of genetic variations and single nucleotide polymorphisms (SNPs). SNPs can determine the likelihood that someone will develop a particular disease. In addition, SNPs can be useful in predetermining a patient's response to drug treatment and can be used as markers to differentiate individuals with varying responses to treatment. Such advances in pharmacogenetics will guide healthcare workers in administering personalized medicine, which is getting just enough of the right medicine to a patient.

"The advent of pharmacogenetics and the increased use of molecular diagnostics as a primary tool for the diagnostician will shift healthcare to a more efficient, more cost-effective system that ultimately provides enhanced care at the individual level,” observed John Blackwood, vice president, global new business development, Bayer HealthCare Diagnostics Division.

Bayer notes that the U.S.$1.9 billion nucleic acid diagnostic market includes testing for infectious and genetic diseases, as well as cell/tissue typing, cancer genetics, and personalized medicine. This is the fastest-growing sector of the diagnostic marketplace, increasing at a rate of 20-40% per year and creating a potential market of $8-10 billion by 2010. ARMS technology has applications throughout this market.




Related Links:
Bayer
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
Automated Blood Typing System
IH-500 NEXT
New
Newborn Screening Test
NeoMass AAAC 3.0
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.